Boutique PR agency recognized for driving credibility and growth across high-impact sectors, including biotechnology, fintech, blockchain, and advanced energy ...
A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
Datavault AI Inc. ('Datavault AI” or the 'Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today ...
2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...
UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and ...
3don MSN
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Now, it’s worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...
Forbes Asia’s 2025 list has the most number of companies from India (18) followed by Singapore and Japan (14 each), China (9) ...
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for ...
A record 1,434 individuals, each with a net worth of more than US$700 million, have made it onto Hurun's list of China's richest people ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
Why does it matter to pharma companies? How Syneos Health Communications can help; Whether you work in healthcare communications, pharmaceutical marketing or biotech ...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Duopharma Biotech Berhad (KLSE:DPHARMA) as an investment opportunity by projecting its future cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback